Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lctx crawled time : 13:00 save search
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
ERNA | $1.8 -8.16% -8.89% 12K
|
Information
|
| O: 4.1%
H: 0.0%
C: -11.81%
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -3.97%
rg6501 opregen innovation cell therapy results study
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
Published: 2023-11-01 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 0.88%
C: -1.75%
report business update cell therapeutics financial results
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: -1.49%
H: 0.76%
C: -3.03%
patent
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
Published: 2023-09-11 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: -2.21%
H: 3.01%
C: 0.0%
international research meeting network trust
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Published: 2023-08-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: -1.44%
H: 6.57%
C: 2.92%
report business update cell therapeutics financial results
22nd Century Announces Executive Leadership Changes
Published: 2023-07-24 (Crawled : 13:00) - globenewswire.com
SMSI 4 | $2.135 0.71% 0.7% 43K
|
Technology Services
|
| O: 1.67%
H: 0.77%
C: -1.64%
OCX | News | $2.3 -6.31% -6.74% 41K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -9.66%
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -1.41%
XXII 4 | $1.845 10.48% 9.49% 1M
|
Health Technology
|
| O: -40.21%
H: 19.31%
C: 7.76%
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
Published: 2023-07-24 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -1.41%
lung report cancer cell treatment research topline therapeutics results study
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.34%
california institute grant
Lineage to Present at 2023 AAPS National Biotechnology Conference
Published: 2023-04-18 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.73%
H: 2.9%
C: 0.72%
conference
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 5.38%
C: 1.54%
report therapeutics financial update results
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
Published: 2022-08-15 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: -0.64%
H: 2.88%
C: 1.92%
conference
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
Published: 2022-06-02 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: -0.79%
H: 5.6%
C: 4.8%
hystem drug collaboration technology
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 2.75%
H: 0.76%
C: -9.16%
report therapeutics results
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2022-05-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 7.56%
H: 1.56%
C: 0.78%
rg6501 opregen disease macular potential phase 1
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
Published: 2022-04-26 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 10.46%
H: 3.79%
C: -2.27%
conference
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
Published: 2022-04-25 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
treatment therapy disease
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
Published: 2022-04-13 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 3.2%
H: 6.2%
C: 2.33%
treatment research cancer enroll phase 1
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
Published: 2022-03-24 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 1.45%
H: 3.57%
C: 2.86%
conference growth group
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
Published: 2021-11-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 5.13%
H: 6.1%
C: 6.1%
financial results results
Lineage Announces Appointment of General Counsel
Published: 2021-09-01 (Crawled : 13:00) - biospace.com/
CRDF | $4.16 -0.24% -0.24% 340K
|
Health Services
|
| O: 0.55%
H: 1.49%
C: -0.68%
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 0.0%
H: 2.78%
C: 1.19%
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.